| Literature DB >> 29278382 |
Xiaohui Lin1, Chao Li2, Yanhui Zhang3, Benzhe Su4, Meng Fan5, Hai Wei6.
Abstract
Feature selection is an important topic in bioinformatics. Defining informative features from complex high dimensional biological data is critical in disease study, drug development, etc. Support vector machine-recursive feature elimination (SVM-RFE) is an efficient feature selection technique that has shown its power in many applications. It ranks the features according to the recursive feature deletion sequence based on SVM. In this study, we propose a method, SVM-RFE-OA, which combines the classification accuracy rate and the average overlapping ratio of the samples to determine the number of features to be selected from the feature rank of SVM-RFE. Meanwhile, to measure the feature weights more accurately, we propose a modified SVM-RFE-OA (M-SVM-RFE-OA) algorithm that temporally screens out the samples lying in a heavy overlapping area in each iteration. The experiments on the eight public biological datasets show that the discriminative ability of the feature subset could be measured more accurately by combining the classification accuracy rate with the average overlapping degree of the samples compared with using the classification accuracy rate alone, and shielding the samples in the overlapping area made the calculation of the feature weights more stable and accurate. The methods proposed in this study can also be used with other RFE techniques to define potential biomarkers from big biological data.Entities:
Keywords: SVM-RFE; feature selection; overlapping degree
Mesh:
Substances:
Year: 2017 PMID: 29278382 PMCID: PMC5943966 DOI: 10.3390/molecules23010052
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Data description.
| Datasets | No. of Samples | No. of Features | No. of Classes |
|---|---|---|---|
| Breast2 [ | 77 | 4869 | 2 |
| Colon [ | 62 | 2000 | 2 |
| DLBCL_GEMS [ | 77 | 5469 | 2 |
| Lymphoma [ | 62 | 4026 | 3 |
| Prostate [ | 102 | 6033 | 2 |
| Brain_data [ | 42 | 5597 | 5 |
| Leukemia2_GEMS [ | 72 | 11225 | 3 |
| Srbct [ | 63 | 2308 | 4 |
Comparison in accuracy (%).
| Datasets | SVM-RFE | SVM-RFE-OA | M-SVM-RFE-OA |
|---|---|---|---|
| Breast2 | 61.96 ± 4.57 | 61.13 | |
| Colon | 80.39 ± 3.99 | 83.92 ± 2.97 | |
| DLBCL_GEMS | 89.09 ± 4.35 | 93.69 ± 2.97 | |
| Lymphoma | 94.14 ± 2.63 | 95.07 ± 2.25 | |
| Prostate | 89.46 ± 2.14 | 91.84 ± 1.82 | |
| Brain_data | 71.78 ± 5.09 | 80.63 ± 4.58 | |
| Leukemia2_GEMS | 89.83 ± 2.80 | 94.39 ± 2.28 | |
| Srbct | 95.21 ± 2.79 | 98.43 ± 1.45 |
Bold: the largest value in a dataset among the three methods.
Comparison in sensitivity (%).
| Datasets | SVM-RFE | SVM-RFE-OA | M-SVM-RFE-OA |
|---|---|---|---|
| Breast2 | 66.95 ± 4.99 | 66.45 ± 4.94 | |
| Colon | 86.35 ± 3.40 | 88.65 ± 2.27 | |
| DLBCL_GEMS | 81.16 ± 8.97 | 88.32 ± 6.49 | |
| Prostate | 89.38 ± 2.67 | 90.23 ± 2.01 |
Bold: the largest value in a dataset among the three methods.
Comparison in specificity (%).
| Datasets | SVM-RFE | SVM-RFE-OA | M-SVM-RFE-OA |
|---|---|---|---|
| Breast2 | 55.27 ± 7.23 | 53.94 ± 7.55 | |
| Colon | 69.45 ± 9.72 | 75.27 ± 6.76 | |
| DLBCL_GEMS | 91.72 ± 4.14 | 95.45 ± 2.78 | |
| Prostate | 89.52 ± 3.65 | 92.48 ± 2.84 |
Bold: the largest value in a dataset among the three methods.
The average number of features selected.
| Datasets | SVM-RFE | SVM-RFE-OA | M-SVM-RFE-OA |
|---|---|---|---|
| Breast2 | 17.54 | 52.34 | 44.89 |
| Colon | 12.41 | 29.46 | 52.36 |
| DLBCL_GEMS | 7.62 | 39.54 | 34.50 |
| Lymphoma | 3.48 | 5.07 | 5.10 |
| Prostate | 12.73 | 60.16 | 57.50 |
| Brain_data | 12.94 | 48.15 | 121.68 |
| Leukemia2_GEMS | 9.61 | 78.49 | 73.99 |
| Srbct | 7.22 | 31.04 | 30.18 |